Genmab — Marts 2013
-
-
ja det er en insiderhandel
-
-
Arzerra maintaince CLL skulle være det vigtigste stuide
-
http://www.sibbing.com/blog/en/tag/daratumumab-en/ Bas har ikke den bedste effekt af dara
-
Hans sygehistorie taget i betragtning er det vel stadig en ganske god effekt fra et Dara synspunkt. Effekt og stabilitet ved ugentlige behandlinger og måske svag negativ effekt ved første 14 dages behandling. men selvfølgelig er det en meget svær situation som patient.
-
var de ikke (endeligt) rimeligt attraktive i kurs
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind